Immunologically induced histamine release from rat peritoneal mast cells is enhanced by low levels of substance P
- PMID: 11239931
- DOI: 10.1016/s0014-2999(01)00805-6
Immunologically induced histamine release from rat peritoneal mast cells is enhanced by low levels of substance P
Abstract
Although direct activation of mast cells by high concentrations (>10(-6) M) of substance P is well established, the effect of sub-micromolar concentrations of the neuropeptide on mast cell activation has not been reported. We hence investigated if substance P would modulate immunologic activation of mast cells by studying the effect of the neuropeptide on anti-rat immunologlobulin E antibody (anti-IgE)-induced histamine release from purified rat peritoneal mast cells. We observed that substance P could dose-dependently potentiate anti-IgE-induced histamine release from rat peritoneal mast cells at concentrations (3x10(-9) M to 3x10(-7) M) which alone induced insignificant or low level of histamine release. While the potentiating effect of substance P was not suppressed by any of the non-peptide tachykinin receptor antagonists CP99994 ((2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine), SR48968 ((S)-N-methyl-N-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl) butyl-benzamide) and SR142801 ((S)-(N)-(1-[3-(1-benzoyl-3(3,4-dichlorophenyl)piperidine-3-yl)propyl]-4-phenylpiperidin-4-yl)-N-methyl-acetamide), it was mimicked by compound 48/80 and suppressed by benzalkonium chloride. Hence, substance P enhanced anti-IgE-induced histamine release through a similar receptor-independent mechanism as the direct mast cell activating action of polybasic compounds. Since high concentrations of substance P required for directly activating mast cells may not be achievable physiologically, the enhancing actions of the neuropeptide on the immunologic activation of mast cells may be more clinically relevant in the pathogenesis of various inflammatory conditions.
Similar articles
-
Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats.Eur J Pharmacol. 1999 Jun 18;374(2):285-91. doi: 10.1016/s0014-2999(99)00338-6. Eur J Pharmacol. 1999. PMID: 10422770
-
Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells.Eur J Pharmacol. 2003 Mar 19;464(2-3):229-35. doi: 10.1016/s0014-2999(03)01430-4. Eur J Pharmacol. 2003. PMID: 12620517
-
Auranofin inhibits histamine release from rat peritoneal mast cells.Int J Immunopharmacol. 1990;12(4):403-7. doi: 10.1016/0192-0561(90)90022-f. Int J Immunopharmacol. 1990. PMID: 1697286
-
Substance P and calcitonin gene-related peptide: effects on mast cells and in human skin.Int Arch Allergy Appl Immunol. 1987;82(3-4):366-71. doi: 10.1159/000234229. Int Arch Allergy Appl Immunol. 1987. PMID: 2437050 Review.
-
Peptidergic pathway in human skin and rat peritoneal mast cell activation.Immunopharmacology. 1994 Jan-Feb;27(1):1-11. doi: 10.1016/0162-3109(94)90002-7. Immunopharmacology. 1994. PMID: 7515863 Review.
Cited by
-
Effects of endogenous substance P expression on degranulation in RBL-2H3 cells.Inflamm Res. 2011 Jun;60(6):541-6. doi: 10.1007/s00011-010-0301-6. Epub 2010 Dec 29. Inflamm Res. 2011. PMID: 21190122
-
Substance P-mediated cardiac mast cell activation: An in vitro study.Neuropeptides. 2019 Apr;74:52-59. doi: 10.1016/j.npep.2019.01.002. Epub 2019 Jan 8. Neuropeptides. 2019. PMID: 30660328 Free PMC article.
-
Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension.Int J Cardiol. 2013 Oct 12;168(5):4643-51. doi: 10.1016/j.ijcard.2013.07.190. Epub 2013 Jul 29. Int J Cardiol. 2013. PMID: 23962787 Free PMC article.
-
Mechanisms underlying the inhibitory effects of tachykinin receptor antagonists on eosinophil recruitment in an allergic pleurisy model in mice.Br J Pharmacol. 2003 Nov;140(5):847-54. doi: 10.1038/sj.bjp.0705515. Br J Pharmacol. 2003. PMID: 14585802 Free PMC article.
-
Mast cell stabilizers: from pathogenic roles to targeting therapies.Front Immunol. 2024 Aug 1;15:1418897. doi: 10.3389/fimmu.2024.1418897. eCollection 2024. Front Immunol. 2024. PMID: 39148726 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources